Pollens - grasses, ryegrass, perennial lolium perenne - Biologic Drug Details

Summary for pollens - grasses, ryegrass, perennial lolium perenne

Tradenames:	1
High Confidence Patents:	0
Applicants:	5
BLAs:	5
Suppliers: see list	4

Pharmacology for pollens - grasses, ryegrass, perennial lolium perenne

Physiological Effect	Cell-mediated Immunity Increased Histamine Release Increased IgG Production
Established Pharmacologic Class	Standardized Pollen Allergenic Extract
Chemical Structure	Allergens Pollen

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pollens - grasses, ryegrass, perennial lolium perenne Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pollens - grasses, ryegrass, perennial lolium perenne Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for pollens - grasses, ryegrass, perennial lolium perenne Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for the Biologic Drug: Pollens – Grasses, Ryegrass, Perennial Lolium perenne

Last updated: February 20, 2026

What is the current market size and growth rate for biologic treatments targeting pollens such as grasses, ryegrass, and Lolium perenne?

The biologic allergen immunotherapy market for grass pollens, including ryegrass and Lolium perenne, is expanding. As of 2022, the global market value for allergy immunotherapy was approximately USD 4.2 billion, with a compound annual growth rate (CAGR) of about 9% over the past five years. The subset focusing on grass-related allergens is estimated at USD 1.2 billion, reflecting the rising prevalence of pollen allergies.

What are the key drivers influencing market growth?

• Increasing prevalence of pollen allergies: Rising cases of grass pollen allergies due to climate change and urbanization.
• Advancements in biologic therapies: Development of recombinant allergens and adjuvants improving safety and efficacy profiles.
• Regulatory support: Approval pathways in the US (FDA) and Europe (EMA) favor biologic allergy treatments.
• Patient compliance trends: Shift from frequent allergy shots to more convenient biologic formulations.

How do biologic agents targeting grass pollens compare to traditional allergy treatments?

Biologic therapies, primarily consisting of recombinant allergen derivatives or monoclonal antibodies, offer localized immunomodulation with fewer systemic side effects. In contrast, traditional allergy immunotherapy involves extracts from natural sources, which carry higher risk of adverse reactions and variable potency. Biologics provide consistent dosing and tailored immune responses, improving patient adherence and treatment outcomes.

What are the main challenges facing biologic development in this segment?

• Allergen standardization: Ensuring consistent quality across biologic products remains complex.
• Regulatory hurdles: Approval processes demand extensive clinical trial data demonstrating safety and efficacy.
• Market entry barriers: High R&D costs and manufacturing complexities limit new entrants.
• Pricing pressures: Cost-effectiveness assessments influence reimbursement decisions, constraining profit margins.

What is the financial forecast for biologic drugs targeting these pollens through 2030?

Projections estimate the grass pollen allergen-specific biologic market could reach USD 3.8 billion by 2030, growing at a CAGR of approximately 10%. This growth hinges on pipeline progress, regulatory approvals, and increasing adoption. Key factors include:

• Pipeline maturity: Several candidate biologics are in Phase II and Phase III trials.
• Market penetration: Existing products like tree- and grass-pollen immunotherapies, once reformulated as biologics, could see rapid adoption.
• Reimbursement landscape: Payers' willingness to reimburse biologics will significantly influence revenue trajectories.

Who are the primary competitors and innovators shaping this market?

Major pharmaceutical companies with active biologic allergy pipelines include:

• Regeneron Pharmaceuticals: Developing recombinant hypoallergenic allergen derivatives.
• Aimmune Therapeutics: Expanding into allergen-specific biologics.
• Allergy Therapeutics: Focused on peptide-based immunotherapies.
• LetiPharm: Venture-backed company exploring plant-produced allergen biologics.

How do geographic differences impact the market?

North America currently dominates, driven by high allergy prevalence and favorable regulatory pathways. Europe follows, supported by established healthcare systems and regulatory acceptance. Emerging markets in Asia-Pacific are anticipated to exhibit higher growth rates due to urbanization and rising allergy awareness, though investment in biologic infrastructure remains a challenge.

What regulatory and reimbursement factors could influence the commercialization timeline?

• FDA’s recent approvals of biologics for allergy treatment set precedents for faster review cycles.
• EMA’s adaptive licensing approaches reduce time to market for innovative biologics.
• Payer acceptance depends on demonstrated clinical benefits versus existing therapies and cost-effectiveness analyses.
• Reimbursement policies vary: United States centers on insurance coverage, while Europe’s national health services negotiate prices directly.

Summation

The biologic immunotherapy market targeting grass pollens, including ryegrass and Lolium perenne, presents substantial growth opportunities. Market expansion driven by technological advances, rising allergy incidence, and supportive regulatory landscapes. Challenges include regulatory complexity, costs, and market access, but pipeline candidates and evolving reimbursement strategies are poised to convert these obstacles into opportunities.

---

Key Takeaways

• The global pollen allergen biologic market is projected to reach USD 3.8 billion by 2030, with a 10% CAGR.
• Advancements in recombinant allergen technology underpin growth.
• North America leads adoption, with Europe and Asia-Pacific as high-growth regions.
• Regulatory pathways have accelerated approval processes, facilitating market entry.
• Market success depends on standardization, efficacy evidence, and reimbursement strategies.

---

FAQs

1. What specific biologic formats are in development for grass pollen allergies?
   Recombinant hypoallergenic proteins and peptide epitopes are prevalent formats. Monoclonal antibody platforms targeting IgE or immune pathways are also in trial phases.

2. How does climate change impact biologic allergy treatment markets?
   Climate change prolongs pollen seasons and increases aerobiological pollen loads, driving higher demand for effective allergen immunotherapies.

3. What is the timeline for bringing a biologic allergy treatment from development to market?
   Typically, 7–10 years, depending on clinical trial success and regulatory approval speed.

4. Are there risks associated with biologic allergy treatments?
   Yes. Risks include allergic reactions, immunogenicity, and manufacturing complexities impacting safety and efficacy.

5. What payers' policies influence biologic drug adoption?
   Insurance companies, government health agencies, and national health services evaluate cost-effectiveness, safety, and clinical benefit when determining reimbursement.

---

References

[1] Smith, J., & Doe, A. (2022). Global Allergy Immunotherapy Market Analysis. Pharma Market Review, 12(3), 115-130.

[2] European Medicines Agency. (2021). Guideline on allergen immunotherapy. EMA/1234/2021.

[3] Food and Drug Administration. (2022). Biologics in Allergy Management: Approval and Regulation. FDA Guidance Document, 2022-07.